182 related articles for article (PubMed ID: 23636640)
1. Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model.
Omar BA; Vikman J; Winzell MS; Voss U; Ekblad E; Foley JE; Ahrén B
Diabetologia; 2013 Aug; 56(8):1752-60. PubMed ID: 23636640
[TBL] [Abstract][Full Text] [Related]
2. Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Miyagawa K; Kondo T; Goto R; Matsuyama R; Ono K; Kitano S; Kawasaki S; Igata M; Kawashima J; Matsumura T; Motoshima H; Araki E
Cardiovasc Diabetol; 2013 Nov; 12():160. PubMed ID: 24188631
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice.
Marques AP; Cunha-Santos J; Leal H; Sousa-Ferreira L; Pereira de Almeida L; Cavadas C; Rosmaninho-Salgado J
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):403-413. PubMed ID: 29154902
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S
Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107
[TBL] [Abstract][Full Text] [Related]
5. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
Apaijai N; Pintana H; Chattipakorn SC; Chattipakorn N
Br J Pharmacol; 2013 Jul; 169(5):1048-57. PubMed ID: 23488656
[TBL] [Abstract][Full Text] [Related]
6. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765
[TBL] [Abstract][Full Text] [Related]
7. ZD-2, a novel DPP4 inhibitor, protects islet β-cell and improves glycemic control in high-fat-diet-induced obese mice.
Fan L; Yang H; Hu X; Liu J; You Y; Li X; Qin G; Ge Q; Hou Y; Xiao X
Life Sci; 2022 Jun; 298():120515. PubMed ID: 35367243
[TBL] [Abstract][Full Text] [Related]
8. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
Utzschneider KM; Tong J; Montgomery B; Udayasankar J; Gerchman F; Marcovina SM; Watson CE; Ligueros-Saylan MA; Foley JE; Holst JJ; Deacon CF; Kahn SE
Diabetes Care; 2008 Jan; 31(1):108-13. PubMed ID: 17909087
[TBL] [Abstract][Full Text] [Related]
9. Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.
Detournay B; Halimi S; Robert J; Deschaseaux C; Dejager S
Vasc Health Risk Manag; 2015; 11():417-25. PubMed ID: 26229480
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice.
Wu YJ; Guo X; Li CJ; Li DQ; Zhang J; Yang Y; Kong Y; Guo H; Liu DM; Chen LM
Metabolism; 2015 Feb; 64(2):226-35. PubMed ID: 25195070
[TBL] [Abstract][Full Text] [Related]
11. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.
Flock G; Baggio LL; Longuet C; Drucker DJ
Diabetes; 2007 Dec; 56(12):3006-13. PubMed ID: 17717280
[TBL] [Abstract][Full Text] [Related]
12. Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet.
Sato K; Nakamura A; Shirakawa J; Muraoka T; Togashi Y; Shinoda K; Orime K; Kubota N; Kadowaki T; Terauchi Y
Endocrinology; 2012 Mar; 153(3):1093-102. PubMed ID: 22315446
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
[TBL] [Abstract][Full Text] [Related]
14. DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats.
Pintana H; Apaijai N; Chattipakorn N; Chattipakorn SC
J Endocrinol; 2013 Jul; 218(1):1-11. PubMed ID: 23591914
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase-4 inhibitor enhances restoration of salivary glands impaired by obese-insulin resistance.
Ittichaicharoen J; Apaijai N; Tanajak P; Sa-Nguanmoo P; Chattipakorn N; Chattipakorn S
Arch Oral Biol; 2018 Jan; 85():148-153. PubMed ID: 29073562
[TBL] [Abstract][Full Text] [Related]
16. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.
Derosa G; Ragonesi PD; Carbone A; Fogari E; D'Angelo A; Cicero AF; Maffioli P
Expert Opin Pharmacother; 2012 Dec; 13(18):2581-91. PubMed ID: 23121473
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats.
Miura K; Kitahara Y; Yamagishi S
Horm Metab Res; 2010 Sep; 42(10):731-5. PubMed ID: 20625970
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of DPP-4 inhibitor Vildagliptin in the management of type-2 diabetes.
Sehra D; Sehra S
J Assoc Physicians India; 2011 Nov; 59():744; author reply 744. PubMed ID: 22616349
[No Abstract] [Full Text] [Related]
19. [Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].
Ito H; Wajima T; Yamaguchi M; Mimori N; Sekiguchi K
Nihon Yakurigaku Zasshi; 2010 Nov; 136(5):299-308. PubMed ID: 21079371
[No Abstract] [Full Text] [Related]
20. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
Ávila Dde L; Araújo GR; Silva M; Miranda PH; Diniz MF; Pedrosa ML; Silva ME; de Lima WG; Costa DC
Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
